KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Novavax's Capital Expenditures rose 47.01% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 72.87%. This contributed to the annual value of $13.1 million for FY2024, which is 75.72% down from last year.
  • Per Novavax's latest filing, its Capital Expenditures stood at $2.0 million for Q3 2025, which was up 716.60% from $247,000 recorded in Q2 2025.
  • Over the past 5 years, Novavax's Capital Expenditures peaked at $24.6 million during Q3 2022, and registered a low of $247,000 during Q2 2025.
  • Over the past 3 years, Novavax's median Capital Expenditures value was $2.9 million (recorded in 2024), while the average stood at $6.4 million.
  • As far as peak fluctuations go, Novavax's Capital Expenditures soared by 10,924.80% in 2021, and later crashed by 92.44% in 2024.
  • Over the past 5 years, Novavax's Capital Expenditures (Quarterly) stood at $13.4 million in 2021, then skyrocketed by 72.08% to $23.0 million in 2022, then plummeted by 61.61% to $8.8 million in 2023, then crashed by 78.14% to $1.9 million in 2024, then skyrocketed by 47.01% to $2.0 million in 2025.
  • Its Capital Expenditures was $2.0 million in Q3 2025, compared to $247,000 in Q2 2025 and $1.2 million in Q1 2025.